USES OF ASGR1 INHIBITOR IN PROMOTING CHOLESTEROL EFFLUX AND TREATING NON-ALCOHOLIC FATTY LIVER DISEASE
The use of an ASGR1 inhibitor in treating non-alcoholic fatty liver disease (NAFLD), the use of an ASGR1 inhibitor in promoting cholesterol efflux, the use of the combination of an ASGR1 inhibitor and a second lipid-lowering drug in treating non-alcoholic fatty liver disease (NAFLD), an anti-ASGR1 m...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WANG, Juqiong SONG, Baoliang |
| description | The use of an ASGR1 inhibitor in treating non-alcoholic fatty liver disease (NAFLD), the use of an ASGR1 inhibitor in promoting cholesterol efflux, the use of the combination of an ASGR1 inhibitor and a second lipid-lowering drug in treating non-alcoholic fatty liver disease (NAFLD), an anti-ASGR1 monoclonal antibody and the use thereof.
L'invention concerne l'utilisation d'un inhibiteur d'ASGR1 dans le traitement d'une stéatose hépatique non alcoolique (NAFLD), l'utilisation d'un inhibiteur d'ASGR1 dans la promotion de l'efflux de cholestérol, l'utilisation de la combinaison d'un inhibiteur d'ASGR1 et d'un second médicament abaissant les lipides dans le traitement d'une stéatose hépatique non alcoolique (NAFLD), un anticorps monoclonal anti-ASGR1 et son utilisation.
ASGR1抑制剂在治疗非酒精性脂肪性肝病(NAFLD)中的应用。ASGR1抑制剂在促进胆固醇外排中的应用。ASGR1抑制剂与第二降脂药的组合在治疗非酒精性脂肪性肝病(NAFLD)中的应用。抗ASGR1单克隆抗体及其用途。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023151624A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023151624A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023151624A13</originalsourceid><addsrcrecordid>eNqNissKwjAQAHvxIOo_LHgumFS9x3TTBmJWkq2PUymSnkQL9f-xiB_gaQZm5lnfRIxABlSsggDra3uwTGEyOAU6Eltfga7JYWQM5ACNcc0VlC-BA6pv9-Rz5TRNm9VgFPMNnD1jgNJGVBGX2azvHmNa_bjI1gZZ13kaXm0ah-6enundXkhuZCF2Yi-3ShT_XR-FgDXv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>USES OF ASGR1 INHIBITOR IN PROMOTING CHOLESTEROL EFFLUX AND TREATING NON-ALCOHOLIC FATTY LIVER DISEASE</title><source>esp@cenet</source><creator>WANG, Juqiong ; SONG, Baoliang</creator><creatorcontrib>WANG, Juqiong ; SONG, Baoliang</creatorcontrib><description>The use of an ASGR1 inhibitor in treating non-alcoholic fatty liver disease (NAFLD), the use of an ASGR1 inhibitor in promoting cholesterol efflux, the use of the combination of an ASGR1 inhibitor and a second lipid-lowering drug in treating non-alcoholic fatty liver disease (NAFLD), an anti-ASGR1 monoclonal antibody and the use thereof.
L'invention concerne l'utilisation d'un inhibiteur d'ASGR1 dans le traitement d'une stéatose hépatique non alcoolique (NAFLD), l'utilisation d'un inhibiteur d'ASGR1 dans la promotion de l'efflux de cholestérol, l'utilisation de la combinaison d'un inhibiteur d'ASGR1 et d'un second médicament abaissant les lipides dans le traitement d'une stéatose hépatique non alcoolique (NAFLD), un anticorps monoclonal anti-ASGR1 et son utilisation.
ASGR1抑制剂在治疗非酒精性脂肪性肝病(NAFLD)中的应用。ASGR1抑制剂在促进胆固醇外排中的应用。ASGR1抑制剂与第二降脂药的组合在治疗非酒精性脂肪性肝病(NAFLD)中的应用。抗ASGR1单克隆抗体及其用途。</description><language>chi ; eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230817&DB=EPODOC&CC=WO&NR=2023151624A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230817&DB=EPODOC&CC=WO&NR=2023151624A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WANG, Juqiong</creatorcontrib><creatorcontrib>SONG, Baoliang</creatorcontrib><title>USES OF ASGR1 INHIBITOR IN PROMOTING CHOLESTEROL EFFLUX AND TREATING NON-ALCOHOLIC FATTY LIVER DISEASE</title><description>The use of an ASGR1 inhibitor in treating non-alcoholic fatty liver disease (NAFLD), the use of an ASGR1 inhibitor in promoting cholesterol efflux, the use of the combination of an ASGR1 inhibitor and a second lipid-lowering drug in treating non-alcoholic fatty liver disease (NAFLD), an anti-ASGR1 monoclonal antibody and the use thereof.
L'invention concerne l'utilisation d'un inhibiteur d'ASGR1 dans le traitement d'une stéatose hépatique non alcoolique (NAFLD), l'utilisation d'un inhibiteur d'ASGR1 dans la promotion de l'efflux de cholestérol, l'utilisation de la combinaison d'un inhibiteur d'ASGR1 et d'un second médicament abaissant les lipides dans le traitement d'une stéatose hépatique non alcoolique (NAFLD), un anticorps monoclonal anti-ASGR1 et son utilisation.
ASGR1抑制剂在治疗非酒精性脂肪性肝病(NAFLD)中的应用。ASGR1抑制剂在促进胆固醇外排中的应用。ASGR1抑制剂与第二降脂药的组合在治疗非酒精性脂肪性肝病(NAFLD)中的应用。抗ASGR1单克隆抗体及其用途。</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNissKwjAQAHvxIOo_LHgumFS9x3TTBmJWkq2PUymSnkQL9f-xiB_gaQZm5lnfRIxABlSsggDra3uwTGEyOAU6Eltfga7JYWQM5ACNcc0VlC-BA6pv9-Rz5TRNm9VgFPMNnD1jgNJGVBGX2azvHmNa_bjI1gZZ13kaXm0ah-6enundXkhuZCF2Yi-3ShT_XR-FgDXv</recordid><startdate>20230817</startdate><enddate>20230817</enddate><creator>WANG, Juqiong</creator><creator>SONG, Baoliang</creator><scope>EVB</scope></search><sort><creationdate>20230817</creationdate><title>USES OF ASGR1 INHIBITOR IN PROMOTING CHOLESTEROL EFFLUX AND TREATING NON-ALCOHOLIC FATTY LIVER DISEASE</title><author>WANG, Juqiong ; SONG, Baoliang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023151624A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng ; fre</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>WANG, Juqiong</creatorcontrib><creatorcontrib>SONG, Baoliang</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WANG, Juqiong</au><au>SONG, Baoliang</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>USES OF ASGR1 INHIBITOR IN PROMOTING CHOLESTEROL EFFLUX AND TREATING NON-ALCOHOLIC FATTY LIVER DISEASE</title><date>2023-08-17</date><risdate>2023</risdate><abstract>The use of an ASGR1 inhibitor in treating non-alcoholic fatty liver disease (NAFLD), the use of an ASGR1 inhibitor in promoting cholesterol efflux, the use of the combination of an ASGR1 inhibitor and a second lipid-lowering drug in treating non-alcoholic fatty liver disease (NAFLD), an anti-ASGR1 monoclonal antibody and the use thereof.
L'invention concerne l'utilisation d'un inhibiteur d'ASGR1 dans le traitement d'une stéatose hépatique non alcoolique (NAFLD), l'utilisation d'un inhibiteur d'ASGR1 dans la promotion de l'efflux de cholestérol, l'utilisation de la combinaison d'un inhibiteur d'ASGR1 et d'un second médicament abaissant les lipides dans le traitement d'une stéatose hépatique non alcoolique (NAFLD), un anticorps monoclonal anti-ASGR1 et son utilisation.
ASGR1抑制剂在治疗非酒精性脂肪性肝病(NAFLD)中的应用。ASGR1抑制剂在促进胆固醇外排中的应用。ASGR1抑制剂与第二降脂药的组合在治疗非酒精性脂肪性肝病(NAFLD)中的应用。抗ASGR1单克隆抗体及其用途。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng ; fre |
| recordid | cdi_epo_espacenet_WO2023151624A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | USES OF ASGR1 INHIBITOR IN PROMOTING CHOLESTEROL EFFLUX AND TREATING NON-ALCOHOLIC FATTY LIVER DISEASE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T15%3A41%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WANG,%20Juqiong&rft.date=2023-08-17&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023151624A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |